NEW YORK (TheStreet) -- CHANGE IN RATINGS:Abbott Laboratories ABT was downgraded at Deutsche Bank from buy to hold. Valuation call, based on a $33 price target, Deutsche said. Aruba Networks ARUN was upgraded at Stifel Nicolaus from hold to buy. $27 price target. Growth could re-accelerate in 2013, Stifel Nicolaus said. The Bank of New York Mellon BK was downgraded at Citigroup to neutral from buy. Valuation call, Citi said. BancorpSouth BXS was downgraded at Keefe, Bruyette & Woods from market perform to underperform. Valuation call, based on a $12 price target, KBW said. Cardinal Health CAH was upgraded at Mizuho from neutral to buy. $46 price target. Company will likely renew two major contracts in 2013, Mizuho said. Continental Resources CLR was initiated with a buy rating at Deutsche Bank. $94 price target. Solid Bakken position can continue to drive growth, Deutsche said. Cepheid CPHD was downgraded at Piper Jaffray from overweight to neutral. $34 price target. See further downside potential to near-term results, Piper Jaffray said. Endo Pharmaceuticals ENDP was downgraded at Piper Jaffray from overweight to neutral. Opana ER is facing generic competition, Piper Jaffray said. $28 price target. Esco Technologies ESE was upgraded at Robert Baird from neutral to outperform. $52 price target. Company should see higher orders in the near term, Robert Baird said. Edwards Lifesciences EW was initiated with a market perform rating at JMP Securities. Company trades at a premium to its peers but has limited upside earnings potential, JMP said. East West Bancorp EWBC was upgraded at Sterne Agee to buy from neutral. $26 price target. Earnings power from expense management, Sterne Agee said. FactSet Research Systems FDS was initiated at Goldman Sachs with a sell rating. $79 price target. Slowing growth and emerging competition, Goldman said. Freescale FSL was downgraded at JP Morgan to neutral. Company could see lower demand and lacks near-term catalysts, JP Morgan said. Illumina ILMN was upgraded at Piper Jaffray from neutral to overweight. $61 price target. Company can continue to gain market share in next-generation sequencing, Piper Jaffray said. Johnson & Johnson JNJ was upgraded at Deutsche Bank to buy. $82 price target. Company has a diversified business and deserves to trade at a premium valuation, Deutsche said. Lululemon LULU was downgraded at Credit Suisse from outperform to neutral. $80 price target. Comp sales growth is slowing, which could weigh on margins, Credit Suisse said. Mattel MAT was upgraded at Needham from hold to buy. Company likely gained market share during the holiday season, Needham said. Shutterfly SFLY was upgraded at Topeka from hold to buy. $40 price target. Have increased confidence in management's ability to deal with increased competition, Topeka said. Texas Roadhouse TXRH was upgraded at Deutsche Bank from hold to buy. $20 price target. Company can continue execute in a difficult environment, Deutsche said. Textron TXT was upgraded at Credit Suisse from neutral to outperform. $30 price target. Market expectations have come down to achievable levels, Credit Suisse said. Under Armour UA was upgraded at Credit Suisse from neutral to outperform. $59 price target. Estimates were also boosted, as the company is leveraged to secular growth trends, Credit Suisse said. Urban Outfitters URBN was upgraded at Credit Suisse from neutral to outperform. $48 price target. Estimates also boosted, given better industry trends, Credit Suisse said. US Bancorp USB was upgraded at Deutsche Bank from hold to buy. $38 price target. Company is best leveraged to reform in the GSE/mortgage space, Deutsche said.
Stock Comments / EPS ChangesDow Chemical DOW numbers were raised at Jefferies. Shares are now seen reaching $34. Estimates were also raised on falling feedstock prices, Jefferies said. Hold rating. Eastman Chemical EMN numbers were raised at Jefferies. Shares are now seen reaching $71. Estimates also raised on lower priced feedstocks, Jefferies said. Hold rating. Endo Health Solutions ENDP numbers were lowered at Oppenheimer. Shares are now seen reaching $32. Estimates were also lowered on generic competition. Outperform rating. Endo Health Solutions numbers were lowered at UBS. Shares are now seen reaching $40. Estimates were also lowered on 2013 guidance, UBS said. Buy rating. Family Dollar FDO numbers were cut at Credit Suisse. Shares are now seen reaching $65. Estimates were also reduced, given the company's new guidance, Credit Suisse said. Outperform rating. Kohl's KSS estimates, target were reduced at Nomura. Estimates were reduced through 2013. Comp sales will likely fall with inventory levels, Nomura said. Neutral rating and new $41 price target. Limited Brands LTD numbers lowered at Nomura. Shares are now seen reaching $52. Estimates were also cut, as the company is seeing lower sales, Nomura said. Buy rating. PPG PPG numbers were raised at UBS. Shares are now seen reaching $136. Estimates were also raised on Deco paints deal, UBS said. Neutral rating. Valero VLO price target was raised at Oppenheimer. Shares are now seen reaching $40. New projects improve outlook, Oppenheimer said. Outperform rating. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.